Enliven Therapeutics, Inc. (ELVN) Stock Research
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Latest price: 45.47 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| Garland J. Scott | sell | 2026-10-01 | 606719.1 |
| Collins Helen Louise | sell | 2026-09-17 | 12355.68 |
| Hohl Benjamin | sell | 2026-09-17 | 111270.47 |
| Hohl Benjamin | sell | 2026-09-17 | 14881.45 |
| Collins Helen Louise | sell | 2026-09-17 | 145890.98 |
| Collins Helen Louise | sell | 2026-09-17 | 93507.21 |
| Hohl Benjamin | sell | 2026-09-17 | 176851.1 |
| Collins Helen Louise | sell | 2026-08-17 | 227649.63 |
| Collins Helen Louise | sell | 2026-08-17 | 65281.15 |
| Hohl Benjamin | sell | 2026-08-17 | 270168.37 |